Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.

Codony-Servat J, Marín-Aguilera M, Visa L, García-Albéniz X, Pineda E, Fernández PL, Filella X, Gascón P, Mellado B.

Prostate. 2013 Apr;73(5):512-21. doi: 10.1002/pros.22591. Epub 2012 Oct 4.

PMID:
23038213
2.

Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.

Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J, Mellado B.

Clin Cancer Res. 2006 Sep 15;12(18):5578-86.

3.

Identification of docetaxel resistance genes in castration-resistant prostate cancer.

Marín-Aguilera M, Codony-Servat J, Kalko SG, Fernández PL, Bermudo R, Buxo E, Ribal MJ, Gascón P, Mellado B.

Mol Cancer Ther. 2012 Feb;11(2):329-39. doi: 10.1158/1535-7163.MCT-11-0289. Epub 2011 Oct 25.

5.

Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy.

Noguchi M, Moriya F, Suekane S, Matsuoka K, Arai G, Matsueda S, Sasada T, Yamada A, Itoh K.

Prostate. 2012 Jun 1;72(8):834-45. doi: 10.1002/pros.21485. Epub 2011 Sep 19.

PMID:
21932426
6.

High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis.

Weichert W, Boehm M, Gekeler V, Bahra M, Langrehr J, Neuhaus P, Denkert C, Imre G, Weller C, Hofmann HP, Niesporek S, Jacob J, Dietel M, Scheidereit C, Kristiansen G.

Br J Cancer. 2007 Aug 20;97(4):523-30. Epub 2007 Jul 10.

7.

Regulation of cell survival by resveratrol involves inhibition of NF kappa B-regulated gene expression in prostate cancer cells.

Benitez DA, Hermoso MA, Pozo-Guisado E, Fernández-Salguero PM, Castellón EA.

Prostate. 2009 Jul 1;69(10):1045-54. doi: 10.1002/pros.20953.

PMID:
19301309
8.

Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.

Marín-Aguilera M, Codony-Servat J, Reig Ò, Lozano JJ, Fernández PL, Pereira MV, Jiménez N, Donovan M, Puig P, Mengual L, Bermudo R, Font A, Gallardo E, Ribal MJ, Alcaraz A, Gascón P, Mellado B.

Mol Cancer Ther. 2014 May;13(5):1270-84. doi: 10.1158/1535-7163.MCT-13-0775. Epub 2014 Mar 21.

9.

Regulation of interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line.

Legrand-Poels S, Schoonbroodt S, Piette J.

Biochem J. 2000 Aug 1;349 Pt 3:765-73.

10.

Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.

Ploussard G, Terry S, Maillé P, Allory Y, Sirab N, Kheuang L, Soyeux P, Nicolaiew N, Coppolani E, Paule B, Salomon L, Culine S, Buttyan R, Vacherot F, de la Taille A.

Cancer Res. 2010 Nov 15;70(22):9253-64. doi: 10.1158/0008-5472.CAN-10-1447. Epub 2010 Nov 2.

11.

Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression.

Uzzo RG, Crispen PL, Golovine K, Makhov P, Horwitz EM, Kolenko VM.

Carcinogenesis. 2006 Oct;27(10):1980-90. Epub 2006 Apr 10.

PMID:
16606632
12.

Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.

Seaton A, Maxwell PJ, Hill A, Gallagher R, Pettigrew J, Wilson RH, Waugh DJ.

Br J Cancer. 2009 Nov 3;101(9):1620-9. doi: 10.1038/sj.bjc.6605356. Epub 2009 Oct 6.

13.

In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.

Sokoloff MH, Tso CL, Kaboo R, Taneja S, Pang S, deKernion JB, Belldegrun AS.

Cancer. 1996 May 1;77(9):1862-72.

14.

Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients.

Montagut C, Tusquets I, Ferrer B, Corominas JM, Bellosillo B, Campas C, Suarez M, Fabregat X, Campo E, Gascon P, Serrano S, Fernandez PL, Rovira A, Albanell J.

Endocr Relat Cancer. 2006 Jun;13(2):607-16.

15.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

16.

[NF-κB subunits regulate maspin expression in prostate cancer cells in vitro].

Ma L, Shen YY, Zhou P, Zhou J, Guo F.

Zhonghua Zhong Liu Za Zhi. 2012 Mar;34(3):165-8. doi: 10.3760/cma.j.issn.0253-3766.2012.03.002. Chinese.

PMID:
22780967
17.

NMDA-induced interleukin-1beta expression is mediated by nuclear factor-kappa B p65 in the retina.

Kitaoka Y, Munemasa Y, Nakazawa T, Ueno S.

Brain Res. 2007 Apr 20;1142:247-55. Epub 2007 Feb 1.

PMID:
17320050
18.

Comparison of the effect of p65 siRNA and curcumin in promoting apoptosis in esophageal squamous cell carcinoma cells and in nude mice.

Tian F, Zhang C, Tian W, Jiang Y, Zhang X.

Oncol Rep. 2012 Jul;28(1):232-40. doi: 10.3892/or.2012.1777. Epub 2012 Apr 23.

PMID:
22552693
19.

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer.

Wilson C, Scullin P, Worthington J, Seaton A, Maxwell P, O'Rourke D, Johnston PG, McKeown SR, Wilson RH, O'Sullivan JM, Waugh DJ.

Br J Cancer. 2008 Dec 16;99(12):2054-64. doi: 10.1038/sj.bjc.6604804. Epub 2008 Dec 2.

20.

Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse.

Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Sauleda S, Alcover J, Campo E, Gascon P, Rovira A, Ross JS, Fernández PL, Albanell J.

Br J Cancer. 2005 Nov 28;93(11):1285-94.

Supplemental Content

Support Center